The temperature-controlled logistics company expects demand to continue, with long-term plans to build out its bioservices operations – and a ‘revolutionary’ cryogenic storage system in the works.
Eversana adopts Cryoport’s full suite of logistics services, in an alliance expected to ‘drive synergistic growth’ for both companies and answer regenerative medicine demands.
Securing the clinical supply chain comes down to the notion of ‘compliance’, which is transitioning from a ‘nice to have’ to a ‘need to have,’ says Cryoport.
Cryoport is supporting a record number of clinical trials driven by rapid growth in regenerative medicine – a space that will continue to grow and outpace the pharmaceutical industry, says CCO.